After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Have you ever felt overwhelmed by juggling multiple apps, emails, and tools just to keep your team on the same page? Imagine a single platform where all your collaboration needs—task management, ...

During the last three months, 4 analysts shared their evaluations of Recursion Pharmaceuticals (NASDAQ:RXRX), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of ...

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...

Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

After numerous leaks and hints, Polar has officially revealed its screenless fitness tracker, Loop. The all-new wearable is essentially a slightly tweaked, consumer-facing version of last year’s B2B ...

In Hans Christian Andersen's folktale, The Emperor's New Clothes, when a child cries out that the emperor is naked, he isn't revealing a secret. Everyone already knows it. What changes in that instant ...

When Everyone Knows That Everyone Knows reveals how shared awareness—the glue of cooperation, coordination, and culture—depends on recursive loops that make us human. These loops—between self and ...

Sound Judgment: “A lot of people didn’t use our products for protection, but for comfort,” says, Loop CEO Dimitri O (right) with cofounder Maarten Bodewes, “comfort that they get through control over ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...